New blood pressure drug HCP1803-4 faces final test
NCT ID NCT07660796
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether a new drug called HCP1803-4 can safely lower blood pressure in adults with essential hypertension. Participants are randomly assigned to receive either the new drug or a control drug. The study measures changes in sitting blood pressure over time to see if the new drug works better or as well as existing options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HCP1803-4
What this could lead to
If successful, this could offer a new treatment option for people with high blood pressure, potentially improving blood pressure control.
What could go wrong
This is a phase 3 trial, but results may not confirm superiority over existing treatments. Side effects are possible, and individual responses may vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Donggguk University Ilsan Hospital
Goyang-si, Gyeonggi-do, 10326, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••